Literature DB >> 179097

Search for antigens and antibodies crossreactive with type C viruses of the woolly monkeys and gibbon ape in animal models and in humans.

J R Stephenson, S A Aaronson.   

Abstract

Several reports have indicated the presence of type-C viral antigens in human tumors and of viruses closely related to those of the woolly monkey and gibbon ape in cultured human cells. In the present studies, attempts to detect woolly monkeys viral antigens in human tissues, or antibodies directed against structural polypeptides of woolly monkey viruses in human sera, were unsuccessful, In contrast, it was possible to demonstrate viral antigens in tissues and antibodies reactive to viral components in several animal and even primate model systems. Further evidence against the presence of woolly monkey viruses in humans is our failure to identify spontaneous or chemically induced viruses of this group in more than 200 individual cultures of human origin examined. These findings argue against the likelihood that viruses closely related to the woolly monkeys virus are associated with human tumors or are common infectious agents of man.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 179097      PMCID: PMC430373          DOI: 10.1073/pnas.73.5.1725

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  TRANSMISSION EXPERIMENTS WITH LEUKEMIA (LYMPHOSARCOMA).

Authors:  W F JARRETT; W B MARTIN; G W CRIGHTON; R G DALTON; M F STEWART
Journal:  Nature       Date:  1964-05-09       Impact factor: 49.962

2.  Isolation of infectious C-type oncornavirus from human leukaemic bone marrow cells.

Authors:  K Nooter; A M Aarssen; P Bentvelzen; F G De Groot; F G Van Pelt
Journal:  Nature       Date:  1975-08-14       Impact factor: 49.962

3.  Immunological and biochemical characterisation of type C viruses isolated from cultured human AML cells.

Authors:  H Okabe; R V Gilden; M Hatanaka; J R Stephenson; R E Gallagher; S A Aaronson; R C Gallo; S R Tronick
Journal:  Nature       Date:  1976-03-18       Impact factor: 49.962

4.  Primate type C virus p30 antigen in cells from humans with acute leukemia.

Authors:  C J Sherr; G J Todaro
Journal:  Science       Date:  1975-03-07       Impact factor: 47.728

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Reverse transcriptases of primate viruses as immunological markers.

Authors:  E M Scolnick; W P Parks; G J Todaro
Journal:  Science       Date:  1972-09-22       Impact factor: 47.728

7.  Appearance of C-type virus-like particles after co-cultivation of a human tumor-cell line with rat (XC) cells.

Authors:  N Gabelman; S Waxman; W Smith; S D Douglas
Journal:  Int J Cancer       Date:  1975-09-15       Impact factor: 7.396

8.  Natural and experimentally induced antibodies to defined mammalian type-C virus proteins in primates.

Authors:  H P Charman; N Kim; M White; H Marquardt; R V Gilden; T Kawakami
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

9.  Growth and differentiation in culture of leukemic leukocytes from a patient with acute myelogenous leukemia and re-identification of type-C virus.

Authors:  R E Gallagher; S Z Salahuddin; W T Hall; K B McCredie; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

10.  Immunological relationship of DNA polymerase from human acute leukaemia cells and primate and mouse leukaemia virus reverse transcriptase.

Authors:  G J Todaro; R C Gallo
Journal:  Nature       Date:  1973-07-27       Impact factor: 49.962

View more
  15 in total

1.  Type C RNA virus-specific antibody in human systemic lupus erythematosus demonstrated by enzymoimmunoassay.

Authors:  R C Mellors; J W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

2.  Human humoral antibodies specific for primate C-type viral antigens.

Authors:  R Kurth; C Schmitt
Journal:  Med Microbiol Immunol       Date:  1977       Impact factor: 3.402

3.  Human antibodies reactive with purified envelope antigens of primate type C tumor viruses.

Authors:  R Kurth; U Mikschy
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

4.  Expression of antigenic crossreactivity to RD114 p 30 protein in a human fibrosarcoma cell line.

Authors:  H S Smith; J L Riggs; E L Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  Isolation and identification of lymphocytic and myelogenous leukemia-specific sequences in genomes of gibbon oncornaviruses.

Authors:  L Sun; T G Kawakami
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

6.  Natural human antibodies reactive with primate type-C viral antigens.

Authors:  R Kurth; N M Teich; R Weiss; R T Oliver
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

7.  Specificity of human antibodies to oncovirus glycoproteins: recognition of antigen by natural antibodies directed against carbohydrate structures.

Authors:  H W Snyder; E Fleissner
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

Review 8.  Human leukemia viruses? RNA tumor viruses, human malignancies, and concepts of viral carcinogenesis.

Authors:  R Hehlmann; V Erfle
Journal:  Blut       Date:  1980-10

9.  Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus.

Authors:  M Barbacid; D Bolognesi; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Type C oncornavirus isolation studies in systemic lupus erythematosus. II. Attempted detection by viral RNA-dependent DNA polymerase assay.

Authors:  P E Phillips; R Hargrave-Granda
Journal:  Ann Rheum Dis       Date:  1978-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.